Research information only — not medical advice. Full disclaimer
Peptide Library

Peptide profile

Fat loss Limited human

Liraglutide

GLP-1 analog for daily weight management

Compare Liraglutide with other peptides →

Summary

Short-acting GLP-1 agonist for weight loss & diabetes.

A daily helper for weight loss and diabetes.

Typical dose
0.6-3.0mg Once daily
Route
Subcutaneous
Cycle length
Ongoing
Evidence
Limited human data

Mechanism

How it works

Liraglutide works like a daily hunger regulator — it stays in your system for about 24 hours, turning the dial down on appetite and turning it up on fullness.

Liraglutide is a GLP-1 receptor agonist with 97% homology to human GLP-1, stimulating insulin secretion, delaying gastric emptying, and reducing appetite.

Liraglutide is a GLP-1 receptor agonist with 97% homology to human GLP-1, stimulating insulin secretion, delaying gastric emptying, and reducing appetite.

Reported in research

Benefits

  • Significant weight loss (5-10% body weight)
  • Improves glycemic control in type 2 diabetes
  • Reduces cardiovascular events
  • Daily dosing (shorter half-life than semaglutide)
  • Helps you lose a good amount of weight (5-10%)
  • Helps control blood sugar in type 2 diabetes
  • Lowers the chance of heart problems
  • Taken once a day (leaves the body faster than semaglutide)

Context, not a prescription

Dosing

Typical range
0.6-3.0mg Once daily (Subcutaneous)
Cycle length
Ongoing

Safety

Side effects & contraindications

Possible side effects

  • Nausea (up to 40%)
  • Vomiting
  • Diarrhea
  • Constipation
  • Pancreatitis
  • Gallbladder disease
  • Medullary thyroid carcinoma risk (rodents)

Contraindications

  • Personal/family history of medullary thyroid carcinoma
  • MEN-2 syndrome
  • Pregnancy or breastfeeding

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Less hunger, weight loss, and better blood sugar.

How it works

Liraglutide works like a daily hunger dial. It stays in your body for about 24 hours. It turns hunger down and the full feeling up.

It turns on GLP-1 signals in your pancreas (to make insulin), your gut (to slow your stomach), and your brain (to feel full).

What to expect

You feel less hungry within hours. You lose a lot of weight by 12-16 weeks.

  • Week 1: You feel less hungry. You might feel a little sick.
  • Weeks 4-8: You slowly start losing weight.
  • Weeks 12-16: You lose the most weight (5-10%).

Good to know

  • Start with the smallest dose (0.6mg)
  • Eat smaller meals that are low in fat
  • Raise the dose slowly over 5 weeks

Staying safe

  • Feeling sick to your stomach (up to 40%)
  • Throwing up
  • Runny poop
  • Hard time pooping

Avoid if you have:

  • People who or whose family had a certain thyroid cancer
  • People with a condition called MEN-2 syndrome
  • People who are pregnant or breastfeeding

Overview

Reduced appetite, weight loss, better blood sugar control.

How it works

Liraglutide works like a daily hunger regulator — it stays in your system for about 24 hours, turning the dial down on appetite and turning it up on fullness.

Activates GLP-1 receptors in pancreas (glucose-dependent insulin), gut (gastric emptying), and hypothalamus (satiety).

Onset & timeline

Appetite suppression within hours; significant weight loss at 12-16 weeks.

  • Week 1: Initial appetite reduction and possible nausea.
  • Weeks 4-8: Progressive weight loss.
  • Weeks 12-16: Maximum weight loss (5-10%).

Getting the most from it

  • Start at lowest dose (0.6mg)
  • Eat smaller, low-fat meals
  • Titrate slowly over 5 weeks

Common side effects

  • Nausea (up to 40%)
  • Vomiting
  • Diarrhea
  • Constipation

Mechanism of action

Liraglutide is a GLP-1 receptor agonist with 97% homology to human GLP-1, stimulating insulin secretion, delaying gastric emptying, and reducing appetite.

Activates GLP-1 receptors in pancreas (glucose-dependent insulin), gut (gastric emptying), and hypothalamus (satiety).

Pharmacodynamics

Appetite suppression within hours; significant weight loss at 12-16 weeks.

Reduced appetite, weight loss, better blood sugar control.

Timeline

  • Week 1: Initial appetite reduction and possible nausea.
  • Weeks 4-8: Progressive weight loss.
  • Weeks 12-16: Maximum weight loss (5-10%).

Comparisons

  • Liraglutide — effectiveness High, safety Good, cost $$$, Easy to use
  • Semaglutide — effectiveness Very High, safety Good, cost $$$, Very Easy to use

Adverse effects

Common:

  • Nausea (up to 40%)
  • Vomiting
  • Diarrhea
  • Constipation

Rare:

  • Pancreatitis
  • Gallbladder disease
  • Medullary thyroid carcinoma risk (rodents)

Contraindications & risk mitigation

Contraindicated in:

  • Personal/family history of medullary thyroid carcinoma
  • MEN-2 syndrome
  • Pregnancy or breastfeeding
  • Start at lowest dose (0.6mg)
  • Eat smaller, low-fat meals
  • Titrate slowly over 5 weeks

Qué hace

Menos hambre, pérdida de peso y mejor azúcar en sangre.

Cómo funciona

La liraglutida funciona como un dial diario para el hambre. Permanece en tu cuerpo durante unas 24 horas. Baja la sensación de hambre y sube la de saciedad.

Activa las señales GLP-1 en tu páncreas (para producir insulina), tu intestino (para ralentizar el estómago) y tu cerebro (para sentirte lleno).

Qué esperar

Sientes menos hambre en pocas horas. Pierdes mucho peso entre las 12 y 16 semanas.

  • Semana 1: Sientes menos hambre. Es posible que te sientas un poco mal del estómago.
  • Semanas 4-8: Empiezas a perder peso poco a poco.
  • Semanas 12-16: Alcanzas la mayor pérdida de peso (5-10%).

Bueno saber

  • Comenzar con la dosis más pequeña (0,6 mg)
  • Comer porciones más pequeñas y bajas en grasa
  • Aumentar la dosis lentamente durante 5 semanas

Manteniéndose seguro

  • Sentirse con náuseas (hasta un 40%)
  • Vómitos
  • Diarrea
  • Estreñimiento

Evitar si tienes:

  • Personas que tengan o hayan tenido antecedentes familiares de cierto tipo de cáncer de tiroides
  • Personas con el síndrome MEN-2
  • Personas embarazadas o en periodo de lactancia

Descripción general

Menor apetito, pérdida de peso y mejor control del azúcar en sangre.

Cómo funciona

La liraglutida funciona como un regulador diario del hambre: permanece en tu sistema durante unas 24 horas, baja el dial del apetito y lo sube en la sensación de saciedad.

Activa los receptores GLP-1 en el páncreas (insulina dependiente de glucosa), el intestino (vaciamiento gástrico) y el hipotálamo (saciedad).

Inicio y cronología

Supresión del apetito en horas; pérdida de peso significativa a las 12-16 semanas.

  • Semana 1: Reducción inicial del apetito y posibles náuseas.
  • Semanas 4-8: Pérdida de peso progresiva.
  • Semanas 12-16: Pérdida de peso máxima (5-10%).

Cómo aprovecharlo al máximo

  • Comenzar con la dosis más baja (0,6 mg)
  • Comer porciones más pequeñas y bajas en grasa
  • Titular lentamente durante 5 semanas

Efectos secundarios comunes

  • Náuseas (hasta un 40%)
  • Vómitos
  • Diarrea
  • Estreñimiento

Mecanismo de acción

La liraglutida es un agonista del receptor GLP-1 con un 97% de homología con el GLP-1 humano, que estimula la secreción de insulina, retrasa el vaciamiento gástrico y reduce el apetito.

Activa los receptores GLP-1 en el páncreas (insulina dependiente de glucosa), el intestino (vaciamiento gástrico) y el hipotálamo (saciedad).

Farmacodinamia

Supresión del apetito en horas; pérdida de peso significativa a las 12-16 semanas.

Menor apetito, pérdida de peso y mejor control del azúcar en sangre.

Cronología

  • Semana 1: Reducción inicial del apetito y posibles náuseas.
  • Semanas 4-8: Pérdida de peso progresiva.
  • Semanas 12-16: Pérdida de peso máxima (5-10%).

Comparaciones

  • Liraglutida — efectividad Alta, seguridad Buena, costo $$$, Fácil de usar
  • Semaglutida — efectividad Muy Alta, seguridad Buena, costo $$$, Muy Fácil de usar

Efectos adversos

Comunes:

  • Náuseas (hasta un 40%)
  • Vómitos
  • Diarrea
  • Estreñimiento

Raros:

  • Pancreatitis
  • Enfermedad de la vesícula biliar
  • Riesgo de carcinoma medular de tiroides (en roedores)

Contraindicaciones y mitigación de riesgos

Contraindicado en:

  • Antecedentes personales o familiares de carcinoma medular de tiroides
  • Síndrome MEN-2
  • Embarazo o lactancia
  • Comenzar con la dosis más baja (0,6 mg)
  • Comer porciones más pequeñas y bajas en grasa
  • Titular lentamente durante 5 semanas

Reference data

Specifications

Route
Subcutaneous
Cycle length
Ongoing

FAQ

Common questions

Is Saxenda the same as Ozempic?

Liraglutide (Saxenda/Victoza) is daily; semaglutide (Ozempic/Wegovy) is weekly and more potent.

Does it cause thyroid cancer?

Risk in humans is not confirmed; contraindicated if family history of medullary thyroid cancer.

What is the evidence level?

This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.

Research

Research & sources

Limited human

Current evidence for Liraglutide is rated as Limited human data. Limited human data is available.

  1. 1. Liraglutide for obesity (SCALE) (2015) — DOI:10.1056/NEJMoa1411892
  2. 2. LEADER trial cardiovascular (2016) — DOI:10.1056/NEJMoa1603827
  3. 3. Liraglutide for obesity (SCALE) (2015)
  4. 4. LEADER trial cardiovascular (2016)